Unicycive Therapeutics Inc. UNCY is a biotechnology company developing drug candidates currently focused on kidney disease. The innovative treatments may have vast potential outside of the specifics of kidney disease as well.
Currently, the company has two treatments in development: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI-494, for treatment of acute kidney injury.
The latter recently passed through a new round of preclinical trials. The results were described as “very encouraging” by a leading expert in the field of AKI (acute kidney injury) research.
Learn more here: Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
Watch the video here:
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Featured photo by National Cancer Institute on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
